Literature DB >> 15244257

Guideline for the management of upper respiratory tract infections.

A J Brink1, M F Cotton, C Feldman, L Geffen, W Hendson, M H Hockman, G Maartens, S A Madhi, M Mutua-Mpungu, G H Swingler.   

Abstract

INTRODUCTION: Inappropriate use of antibiotics for upper respiratory tract infections (URTIs), many of which are viral, adds to the burden of antibiotic resistance. Antibiotic resistance is increasing in Streptococcus pneumoniae, responsible for most cases of acute otitis media (AOM) and acute bacterial sinusitis (ABS).
METHOD: The Infectious Diseases Society of Southern Africa held a multidisciplinary meeting to draw up a national guideline for the management of URTIs. Background information reviewed included randomised controlled trials, existing URTI guidelines and local antibiotic susceptibility patterns. The initial document was drafted at the meeting. Subsequent drafts were circulated to members of the working group for modification. The guideline is a consensus document based upon the opinions of the working group. OUTPUT: Penicillin remains the drug of choice for tonsillopharyngitis. Single-dose parenteral administration of benzathine penicillin is effective, but many favour oral administration twice daily for 10 days. Amoxycillin remains the drug of choice for both AOM and ABS. A dose of 90 mg/ kg/day is recommended in general, which should be effective for pneumococci with high-level penicillin resistance (this is particularly likely in children < or = 2 years of age, in day-care attendees, in cases with prior AOM within the past 6 months, and in children who have received antibiotics within the last 3 months). Alternative antibiotic choices are given in the guideline with recommendations for their specific indications. These antibiotics include amoxycillin-clavulanate, some cephalosporins, the macrolide/azalide and ketolide groups of agents and the respiratory fluoroquinolones.
CONCLUSION: The guideline should assist rational antibiotic prescribing for URTIs. However, it should be updated when new information becomes available from randomised controlled trials and surveillance studies of local antibiotic susceptibility patterns.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15244257

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

1.  Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study.

Authors:  J R Snyman; H S Schoeman; M P Grobusch; M Henning; W Rabie; M Hira; K Parshotam; Y Mithal; S Singh; Z Ramdas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

2.  The co-selection of fluoroquinolone resistance genes in the gut flora of Vietnamese children.

Authors:  Le Thi Minh Vien; Ngo Ngoc Quang Minh; Tang Chi Thuong; Huynh Duy Khuong; Tran Vu Thieu Nga; Corinne Thompson; James I Campbell; Menno de Jong; Jeremy J Farrar; Constance Schultsz; H Rogier van Doorn; Stephen Baker
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

3.  Drug management in chronic rhinosinusitis: identification of the needs.

Authors:  Jean-Baptiste Hpj Watelet; Philippe H Eloy; Paul B van Cauwenberge
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

4.  Bacterial and Respiratory Viral Interactions in the Etiology of Acute Otitis Media in HIV-infected and HIV-uninfected South African Children.

Authors:  Shabir A Madhi; Niresha Govender; Kishen Dayal; Raghavendra Devadiga; Melissa K Van Dyke; Nadia van Niekerk; Clare Louise Cutland; Peter V Adrian; Marta C Nunes
Journal:  Pediatr Infect Dis J       Date:  2015-07       Impact factor: 2.129

5.  Magnitude and factors associated with upper respiratory tract infection among under-five children in public health institutions of Aksum town, Tigray, Northern Ethiopia: an institutional based cross-sectional study.

Authors:  Teklay Zeru; Hagos Berihu; Gerezgiher Buruh; Haftom Gebrehiwot
Journal:  Pan Afr Med J       Date:  2020-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.